Effects of gabapentin on morphine consumption and pain in severely burned patients
Abstract Objective Nociception is the major cause of burn pain and leads to central hyperalgesia. Gabapentin ( Gp ) is an antihyperalgesic drug that selectively affects central sensitization. We studied the opioid-sparing and analgesic effects of Gp in severely burned patients. Methods Ten patients...
Gespeichert in:
| Veröffentlicht in: | Burns 2007-02, Vol.33 (1), p.81-86 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 86 |
|---|---|
| container_issue | 1 |
| container_start_page | 81 |
| container_title | Burns |
| container_volume | 33 |
| creator | Cuignet, Olivier Pirson, Jean Soudon, Olivier Zizi, Martin |
| description | Abstract Objective Nociception is the major cause of burn pain and leads to central hyperalgesia. Gabapentin ( Gp ) is an antihyperalgesic drug that selectively affects central sensitization. We studied the opioid-sparing and analgesic effects of Gp in severely burned patients. Methods Ten patients (mean total burned body surface area (TBSA), 25%), received 2400 mg of oral Gp daily from after burn days 3–24 in addition to standard pain therapy. They were compared to a retrospective matching group. Outcomes were cumulative morphine consumption and mean daily pain scores. Outcomes were recorded during treatment (21 days) and 21 days after treatment. Results During treatment and post-treatment phases, patients receiving Gp had cumulative morphine consumption and a mean daily pain score significantly lower than controls. Conclusion Gp use reduced opioid consumption and lowered pain scores that seemed to extend beyond its pharmacologic action probably result from the ability of Gp to prevent central hyperalgesia induced by burns. |
| doi_str_mv | 10.1016/j.burns.2006.04.020 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68420726</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0305417906001525</els_id><sourcerecordid>68420726</sourcerecordid><originalsourceid>FETCH-LOGICAL-c468t-a045a4ca0d5226a37f34ccc325906dddb8a3874a743b5d728d262af4f91a268a3</originalsourceid><addsrcrecordid>eNqFkV9r1TAYh4Mo7mz6CQTpjd61e5OmSXqhIGPOwUDY9Dqk-aM5tklN2sH59qaeAwNvDIFA8vzevDwvQm8wNBgwu9w3w5pCbggAa4A2QOAZ2mHB-xpT6J-jHbTQ1RTz_gyd57yHsjoBL9EZ5sAxANmh-2vnrF5yFV31Qw1qtmHxoYqhmmKaf_pgKx1DXqd58eVSBVPNqgBlZ_tokx0P1daG3e4XX9L5FXrh1Jjt69N5gb5_vv529aW--3pze_XprtaUiaVWQDtFtQLTEcJUy11LtdYt6XpgxphBqFZwqjhth85wIgxhRDnqeqwIK48X6P2x7pzi79XmRU4-azuOKti4ZskEJcAJK2B7BHWKOSfr5Jz8pNJBYpCbSrmXf1XKTaUEKovKknp7Kr8OkzVPmZO7Arw7ASprNbqkgvb5iROU4l5s3384crbIePQ2yayLKG2NT0W9NNH_p5GP_-T16IMvX_6yB5v3sSSKZ4llJhLkwzb1bejAAHBHuvYPWYqoCg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68420726</pqid></control><display><type>article</type><title>Effects of gabapentin on morphine consumption and pain in severely burned patients</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Cuignet, Olivier ; Pirson, Jean ; Soudon, Olivier ; Zizi, Martin</creator><creatorcontrib>Cuignet, Olivier ; Pirson, Jean ; Soudon, Olivier ; Zizi, Martin</creatorcontrib><description>Abstract Objective Nociception is the major cause of burn pain and leads to central hyperalgesia. Gabapentin ( Gp ) is an antihyperalgesic drug that selectively affects central sensitization. We studied the opioid-sparing and analgesic effects of Gp in severely burned patients. Methods Ten patients (mean total burned body surface area (TBSA), 25%), received 2400 mg of oral Gp daily from after burn days 3–24 in addition to standard pain therapy. They were compared to a retrospective matching group. Outcomes were cumulative morphine consumption and mean daily pain scores. Outcomes were recorded during treatment (21 days) and 21 days after treatment. Results During treatment and post-treatment phases, patients receiving Gp had cumulative morphine consumption and a mean daily pain score significantly lower than controls. Conclusion Gp use reduced opioid consumption and lowered pain scores that seemed to extend beyond its pharmacologic action probably result from the ability of Gp to prevent central hyperalgesia induced by burns.</description><identifier>ISSN: 0305-4179</identifier><identifier>EISSN: 1879-1409</identifier><identifier>DOI: 10.1016/j.burns.2006.04.020</identifier><identifier>PMID: 17071002</identifier><identifier>CODEN: BURND8</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject><![CDATA[Administration, Oral ; Amines - administration & dosage ; Analgesics - administration & dosage ; Antihyperalgesic ; Biological and medical sciences ; Burn pain ; Burns ; Burns - complications ; Case-Control Studies ; Critical Care ; Cyclohexanecarboxylic Acids - administration & dosage ; Female ; Gabapentin ; gamma-Aminobutyric Acid - administration & dosage ; Humans ; Male ; Medical sciences ; Middle Aged ; Morphine - administration & dosage ; Pain - prevention & control ; Pain Measurement ; Spinal sensitization ; Traumas. Diseases due to physical agents ; Treatment Outcome]]></subject><ispartof>Burns, 2007-02, Vol.33 (1), p.81-86</ispartof><rights>Elsevier Ltd and ISBI</rights><rights>2006 Elsevier Ltd and ISBI</rights><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c468t-a045a4ca0d5226a37f34ccc325906dddb8a3874a743b5d728d262af4f91a268a3</citedby><cites>FETCH-LOGICAL-c468t-a045a4ca0d5226a37f34ccc325906dddb8a3874a743b5d728d262af4f91a268a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.burns.2006.04.020$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18441986$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17071002$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cuignet, Olivier</creatorcontrib><creatorcontrib>Pirson, Jean</creatorcontrib><creatorcontrib>Soudon, Olivier</creatorcontrib><creatorcontrib>Zizi, Martin</creatorcontrib><title>Effects of gabapentin on morphine consumption and pain in severely burned patients</title><title>Burns</title><addtitle>Burns</addtitle><description>Abstract Objective Nociception is the major cause of burn pain and leads to central hyperalgesia. Gabapentin ( Gp ) is an antihyperalgesic drug that selectively affects central sensitization. We studied the opioid-sparing and analgesic effects of Gp in severely burned patients. Methods Ten patients (mean total burned body surface area (TBSA), 25%), received 2400 mg of oral Gp daily from after burn days 3–24 in addition to standard pain therapy. They were compared to a retrospective matching group. Outcomes were cumulative morphine consumption and mean daily pain scores. Outcomes were recorded during treatment (21 days) and 21 days after treatment. Results During treatment and post-treatment phases, patients receiving Gp had cumulative morphine consumption and a mean daily pain score significantly lower than controls. Conclusion Gp use reduced opioid consumption and lowered pain scores that seemed to extend beyond its pharmacologic action probably result from the ability of Gp to prevent central hyperalgesia induced by burns.</description><subject>Administration, Oral</subject><subject>Amines - administration & dosage</subject><subject>Analgesics - administration & dosage</subject><subject>Antihyperalgesic</subject><subject>Biological and medical sciences</subject><subject>Burn pain</subject><subject>Burns</subject><subject>Burns - complications</subject><subject>Case-Control Studies</subject><subject>Critical Care</subject><subject>Cyclohexanecarboxylic Acids - administration & dosage</subject><subject>Female</subject><subject>Gabapentin</subject><subject>gamma-Aminobutyric Acid - administration & dosage</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Morphine - administration & dosage</subject><subject>Pain - prevention & control</subject><subject>Pain Measurement</subject><subject>Spinal sensitization</subject><subject>Traumas. Diseases due to physical agents</subject><subject>Treatment Outcome</subject><issn>0305-4179</issn><issn>1879-1409</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkV9r1TAYh4Mo7mz6CQTpjd61e5OmSXqhIGPOwUDY9Dqk-aM5tklN2sH59qaeAwNvDIFA8vzevDwvQm8wNBgwu9w3w5pCbggAa4A2QOAZ2mHB-xpT6J-jHbTQ1RTz_gyd57yHsjoBL9EZ5sAxANmh-2vnrF5yFV31Qw1qtmHxoYqhmmKaf_pgKx1DXqd58eVSBVPNqgBlZ_tokx0P1daG3e4XX9L5FXrh1Jjt69N5gb5_vv529aW--3pze_XprtaUiaVWQDtFtQLTEcJUy11LtdYt6XpgxphBqFZwqjhth85wIgxhRDnqeqwIK48X6P2x7pzi79XmRU4-azuOKti4ZskEJcAJK2B7BHWKOSfr5Jz8pNJBYpCbSrmXf1XKTaUEKovKknp7Kr8OkzVPmZO7Arw7ASprNbqkgvb5iROU4l5s3384crbIePQ2yayLKG2NT0W9NNH_p5GP_-T16IMvX_6yB5v3sSSKZ4llJhLkwzb1bejAAHBHuvYPWYqoCg</recordid><startdate>20070201</startdate><enddate>20070201</enddate><creator>Cuignet, Olivier</creator><creator>Pirson, Jean</creator><creator>Soudon, Olivier</creator><creator>Zizi, Martin</creator><general>Elsevier Ltd</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20070201</creationdate><title>Effects of gabapentin on morphine consumption and pain in severely burned patients</title><author>Cuignet, Olivier ; Pirson, Jean ; Soudon, Olivier ; Zizi, Martin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c468t-a045a4ca0d5226a37f34ccc325906dddb8a3874a743b5d728d262af4f91a268a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Administration, Oral</topic><topic>Amines - administration & dosage</topic><topic>Analgesics - administration & dosage</topic><topic>Antihyperalgesic</topic><topic>Biological and medical sciences</topic><topic>Burn pain</topic><topic>Burns</topic><topic>Burns - complications</topic><topic>Case-Control Studies</topic><topic>Critical Care</topic><topic>Cyclohexanecarboxylic Acids - administration & dosage</topic><topic>Female</topic><topic>Gabapentin</topic><topic>gamma-Aminobutyric Acid - administration & dosage</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Morphine - administration & dosage</topic><topic>Pain - prevention & control</topic><topic>Pain Measurement</topic><topic>Spinal sensitization</topic><topic>Traumas. Diseases due to physical agents</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cuignet, Olivier</creatorcontrib><creatorcontrib>Pirson, Jean</creatorcontrib><creatorcontrib>Soudon, Olivier</creatorcontrib><creatorcontrib>Zizi, Martin</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Burns</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cuignet, Olivier</au><au>Pirson, Jean</au><au>Soudon, Olivier</au><au>Zizi, Martin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of gabapentin on morphine consumption and pain in severely burned patients</atitle><jtitle>Burns</jtitle><addtitle>Burns</addtitle><date>2007-02-01</date><risdate>2007</risdate><volume>33</volume><issue>1</issue><spage>81</spage><epage>86</epage><pages>81-86</pages><issn>0305-4179</issn><eissn>1879-1409</eissn><coden>BURND8</coden><abstract>Abstract Objective Nociception is the major cause of burn pain and leads to central hyperalgesia. Gabapentin ( Gp ) is an antihyperalgesic drug that selectively affects central sensitization. We studied the opioid-sparing and analgesic effects of Gp in severely burned patients. Methods Ten patients (mean total burned body surface area (TBSA), 25%), received 2400 mg of oral Gp daily from after burn days 3–24 in addition to standard pain therapy. They were compared to a retrospective matching group. Outcomes were cumulative morphine consumption and mean daily pain scores. Outcomes were recorded during treatment (21 days) and 21 days after treatment. Results During treatment and post-treatment phases, patients receiving Gp had cumulative morphine consumption and a mean daily pain score significantly lower than controls. Conclusion Gp use reduced opioid consumption and lowered pain scores that seemed to extend beyond its pharmacologic action probably result from the ability of Gp to prevent central hyperalgesia induced by burns.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>17071002</pmid><doi>10.1016/j.burns.2006.04.020</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0305-4179 |
| ispartof | Burns, 2007-02, Vol.33 (1), p.81-86 |
| issn | 0305-4179 1879-1409 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68420726 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Administration, Oral Amines - administration & dosage Analgesics - administration & dosage Antihyperalgesic Biological and medical sciences Burn pain Burns Burns - complications Case-Control Studies Critical Care Cyclohexanecarboxylic Acids - administration & dosage Female Gabapentin gamma-Aminobutyric Acid - administration & dosage Humans Male Medical sciences Middle Aged Morphine - administration & dosage Pain - prevention & control Pain Measurement Spinal sensitization Traumas. Diseases due to physical agents Treatment Outcome |
| title | Effects of gabapentin on morphine consumption and pain in severely burned patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T23%3A45%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20gabapentin%20on%20morphine%20consumption%20and%20pain%20in%20severely%20burned%20patients&rft.jtitle=Burns&rft.au=Cuignet,%20Olivier&rft.date=2007-02-01&rft.volume=33&rft.issue=1&rft.spage=81&rft.epage=86&rft.pages=81-86&rft.issn=0305-4179&rft.eissn=1879-1409&rft.coden=BURND8&rft_id=info:doi/10.1016/j.burns.2006.04.020&rft_dat=%3Cproquest_cross%3E68420726%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68420726&rft_id=info:pmid/17071002&rft_els_id=1_s2_0_S0305417906001525&rfr_iscdi=true |